Logo

CPIX

Cumberland Pharmaceuticals Inc.

CPIX

Cumberland Pharmaceuticals Inc. • NASDAQ
$2.26 ▲ 2.26% (+0.05)
Market Cap $33.80 M
52w High $7.25
52w Low $1.09
Dividend Yield 0%
P/E -9.42
Volume 37.83K
Outstanding Shares 14.96M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $8.292M ▼ $9.269M ▼ $-1.941M ▼ -23.404% ▼ $-0.13 ▼ $-795.873K ▼
Q2-2025 $10.837M ▼ $9.573M ▲ $-740.74K ▼ -6.835% ▼ $-0.05 ▼ $699.114K ▼
Q1-2025 $11.713M ▲ $8.995M ▼ $1.257M ▲ 10.732% ▲ $0.08 ▲ $2.734M ▲
Q4-2024 $10.436M ▲ $10.301M ▲ $-1.904M ▼ -18.244% ▼ $-0.14 ▼ $46.207K ▲
Q3-2024 $9.086M $9.457M $-1.544M -16.994% $-0.11 $13.067K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.197M ▼ $65.899M ▼ $40.098M ▼ $26.12M ▼
Q2-2025 $16.087M ▲ $67.907M ▼ $40.228M ▼ $27.99M ▼
Q1-2025 $15.108M ▼ $69.936M ▼ $41.595M ▼ $28.657M ▲
Q4-2024 $17.964M ▲ $75.583M ▼ $53.037M ▲ $22.853M ▼
Q3-2024 $17.465M $76.748M $52.278M $24.779M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.941M ▼ $187.18K ▼ $-690.837K ▼ $-386.879K ▼ $-890.536K ▼ $163.39K ▼
Q2-2025 $-740.74K ▼ $843.801K ▼ $285.864K ▲ $-150.797K ▲ $978.868K ▲ $817.315K ▼
Q1-2025 $1.248M ▲ $3.899M ▲ $-1.228M ▼ $-5.526M ▼ $-2.856M ▼ $3.851M ▲
Q4-2024 $-1.902M ▼ $1.905M ▲ $-26.809K ▼ $-1.378M ▼ $499.43K ▲ $1.878M ▲
Q3-2024 $-1.537M $475.503K $189.641K $-536.836K $128.308K $516.315K

Revenue by Products

Product Q3-2024Q1-2025Q2-2025Q3-2025
Product Other
Product Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Product Vibativ
Product Vibativ
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Cumberland looks like a small, stable but not yet truly profitable business. Sales have been fairly flat for several years, with decent product margins, but overhead and development costs keep overall operating results in the red. Net income has been consistently negative, and per‑share losses have drifted slightly worse over time. In simple terms, the company is covering the cost of making its drugs but not fully covering the broader costs of running and growing the business.

Balance Sheet

Balance Sheet The balance sheet is modest but not overly stretched. Total assets have edged down a bit, and the cash balance is steady but not large, suggesting a limited cushion rather than a deep war chest. Debt levels are relatively small and have not been increasing, which helps keep financial risk contained. Equity has been gradually shrinking due to ongoing losses, signaling that the company has less financial buffer than a few years ago, but it does not appear heavily indebted.

Cash Flow

Cash Flow Cash generation is close to break-even. Operations have tended to produce only a small amount of cash, and in the most recent period this moved to roughly neutral. The business does not require heavy investment in physical assets, so capital spending is light, and free cash flow has hovered around zero. This means the company is more or less funding itself day‑to‑day, but it has limited internal cash to support bigger expansion or setbacks without either improving profitability or finding outside funding.

Competitive Edge

Competitive Edge Cumberland occupies a narrow but defensible niche in hospital and specialist medicines. Its products tend to be differentiated by formulation, delivery method, or safety profile rather than by being the cheapest options. Having multiple FDA‑approved brands across acute care, oncology, and gastroenterology gives it a diversified, though still small, revenue base. Partnerships and licensing deals, like the co‑promotion of Talicia and international launches of key drugs, extend its reach beyond what its size alone would usually allow. However, it still competes with much larger pharmaceutical companies, faces potential generic and pricing pressure, and relies heavily on a handful of flagship products, which concentrates risk.

Innovation and R&D

Innovation and R&D Innovation at Cumberland is focused on improving how existing medicines are delivered and on a single, potentially high‑impact pipeline drug, ifetroban. The marketed portfolio includes novel formulations and delivery systems—such as an intravenous ibuprofen with safety advantages and a chemotherapy nausea patch that stands out as the only one of its kind. On the R&D side, ifetroban is being tested for several rare, serious conditions and has received special regulatory designations that could speed development and enhance its value if successful. At the same time, these programs are still in mid‑stage trials, so scientific, regulatory, and commercial uncertainty remains high, and the company’s future growth story leans heavily on these outcomes.

Summary

Overall, Cumberland looks like a small specialty pharma company with a stable but low-growth revenue base, persistent but manageable losses, and a balance sheet that is adequate rather than strong. The business is built around differentiated hospital and specialist drugs, supported by partnerships and selective international expansion, which together provide some competitive resilience despite its limited scale. The main potential upside lies in its rare-disease pipeline, particularly ifetroban, which could reshape the company if the trials succeed and products reach the market. The main risks are its continued lack of meaningful profit, dependence on a limited number of products and partners, and the inherent uncertainty of drug development and pricing pressures in healthcare.

NEWS

November 4, 2025 · 5:00 PM UTC

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Read more

October 28, 2025 · 4:05 PM UTC

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Read more

October 20, 2025 · 9:05 AM UTC

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Read more

October 20, 2025 · 9:00 AM UTC

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Read more

October 13, 2025 · 9:05 AM UTC

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Read more